These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3157571)

  • 1. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
    Fosså SD; Jahnsen JU; Karlsen S; Ogreid P; Haveland H; Trovåg A
    Eur Urol; 1985; 11(1):11-6. PubMed ID: 3157571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.
    Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P
    Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J; Spona J
    Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients.
    Martoni A; Longhi A; Canova N; Pannuti F
    Oncology; 1991; 48(1):1-6. PubMed ID: 1824798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
    Sasagawa I; Satomi S
    Br J Urol; 1990 Mar; 65(3):278-81. PubMed ID: 1692498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.
    Gallagher CJ; Cairnduff F; Smith IE
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1895-900. PubMed ID: 2963746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.
    Nilsson TK; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 1989; 23(1):11-4. PubMed ID: 2522237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
    Damber JE; Bergh A; Landström M; Tomić R
    J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
    Petru E; Schmähl D
    Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.